The Future Of Photochemistry
News Feb 26, 2014
Two years in development, the plug and play reactor offers a wide range of features that makes it an industry first. With no intensive set up required, it is unique within the field of flow chemistry and is designed to complement Vapourtec’s existing R-Series and E-Series flow chemistry systems used in hundreds of laboratories around the world.
The UV-150 allows for safe access to photo chemistry processes that hasn’t existed before due to the unique design of the 150 Watt lamp, filters and reactors that deliver enhanced power, analytics and temperature control. The reactor, around 10% of the volume of other reactors that offer similar throughput, operates between -5° and 80°C.
Dr Duncan Browne, an experienced post-doc and flow chemist involved in research using the UV-150 at the Ley Group, Cambridge commented: “The benefits accrued from the combination of photochemistry and flow methods were demonstrated in the first report from Booker-Milburn and Berry*. However, the modularity, convenience and compact scale of the Vapourtec system sets-up the opportunity for a great deal more chemists to explore the area of photochemically induced reactions leading to interesting and functionalisable building blocks. Ready access to such important techniques can only ever benefit synthesis chemistry.”
According to Vapourtec Managing Director Duncan Guthrie, the new reactor could have a dramatic impact on the potential of photochemistry within continuous flow processing: “The UV-150 is a truly unique innovation that gives chemists the opportunity to develop ‘reagent less’ and scalable manufacturing of new and existing compounds and is a far more efficient alternative to traditional batch chemistry approaches.
“Current green photochemistry processes can be hazardous due to the lack of control and scalability inherent within traditional batch systems. The plug and play nature of the continuous processing UV-150 makes it easy to use with a small dedicated power supply and a patented cooling system delivering additional advantages.
“There is real physics behind the UV-150 with a compact high intensity 150 watt lamp, temperature control, wavelength filtering and reflective surfaces all designed to ensure that the photons emitted by the lamp are efficiently absorbed by the reagents. Provision has even been made for mounting an optional spectrometer, this feature allows the absorption by the reagents to be monitored in real time which is yet another unique feature.
“Artemisinin, currently the most effective treatment against malaria, is a perfect example of what can be achieved using photochemistry within a continuous flow synthesis.
“In late 2011 Professor Dr Seeberger and Dr Levesque of the Max Planck Institute reported on a continuous flow conversion of dihydroartemisinic acid, extracted from sweet wormwood (Artemisia annua), into artemisinin with a continuous photochemical transformation central to the reaction.
“There is currently nothing as efficient and easy-to-use as this reactor available in the field of flow chemistry and we are convinced that it will play a pivotal role in many chemical and pharmaceutical breakthroughs in the future.
“Despite still being an underutilised technique, there is growing interest in photochemistry and this is a perfect fit for industry requirements. This is the biggest innovation we have developed so far and there is genuine interest and application within many fields including academic research, pharma, environmental and industrial chemistry,” added Duncan.
Vapourtec design and manufacture flow chemistry systems for a wide variety of sectors across the globe including education, pharmaceutical and industry and their technology has been cited as playing a pivotal part in recent major research breakthroughs.
Established in 2003, Vapourtec has developed a flourishing international market for its technology with sales across much of the developed world including USA, China, Japan, Singapore and India.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018